Phenylalanine MarketSize and Trends

Phenylalanine Market Drivers

Increasing prevalence of anxiety and depression are responsible for massive consumptions of anti-depressants, in turn promoting global phenylalanine market growth. For instance, according to the World Health Organization (WHO) data findings, in 2017, over 300 million people of all ages are suffering from depression worldwide, wherein around 800,000 people die due to suicide due to anxiety disorders and depression as prime cause. Moreover, according to the National Institute of Mental Health (NIMH), in 2016, an estimated 10.3 million U.S. adults (4.3% of all U.S. adults) aged 18 or older had at least one major depressive episode with severe impairment. Furthermore, according to the same source, the prevalence of major depressive cases was higher among adult females (8.5%) as compared to males (4.8%). Furthermore, the prevalence of adults with a major depressive episode was highest among individuals aged 18-25 (10.9%). The association (NIMH) also mentions that these disorders are highly treatable thereby propelling opportunities for growth of the global phenylalanine market.

Moreover, high prevalence of chronic pain diseases is expected to foster the growth of phenylalanine market over the forecast period. For instance, according to the American Academy of Pain Medicine (AAPM), in 2011, around 1.8 billion people suffered from chronic pain. Moreover, the National Institutes of Health (NIH) estimates that one in 10 people in the U.S. suffer from chronic pain. According to a study published in the British Medical Journal in 2016, nearly one-third to half of the population in the U.K. suffers from chronic pain. Moreover, according to the NIH estimates published in 2015 by the American Pain Society, around 50 million people in the U.S. suffered from chronic pain.

Furthermore, increasing prevalence of pain and chronic diseases such as cancer and others are driving growth of the phenylalanine market. For instance, according to the National Cancer Institute, in 2018, around 1,735,350 new cases of cancer are expected to be diagnosed in the U.S. and 609,640 people are expected to die from the disease.